Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in 1 story
The narratives 2196.HK currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
2196.HK in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Its controlling interest in Henlius gives it exposure to globally licensed Chinese biologics including serplulimab and multiple biosimilars.
Bear side
0 storiesNo bear-side stories for 2196.HK yet.